



Press release |

IBA COMPLETES PROTON THERAPY SYSTEM AND FIRST TREATMENT ROOM IN RECORD TIME OF 1 YEAR, AT PROCURE'S SEATTLE CENTER

Seattle, Washington, USA, January 31, 2013 — IBA (Ion Beam Applications S.A.), the global high-tech leader in next generation radiation therapy and diagnostics for the treatment of cancer, is pleased to announce that it continues to accelerate the pace at which newly constructed proton therapy centers are ready to treat patients. This unrivalled capacity of installing proton centers reduces the technological and financial risk for the stakeholders, hence making IBA the safest choice in the market today.

IBA has installed a cyclotron, beam line and the first of four state-of-the art treatment rooms at the accelerated pace of just 12 months from the delivery of the building (Building Occupancy Date). The fast turnaround at the ProCure Proton Therapy Center demonstrates that once again IBA is the leading provider of integrated proton therapy solutions that can be installed and clinically functional in an unrivalled time period.

Clinicians expect to treat the first patient at the end of the first quarter 2013. This is an important milestone in bringing this compassionate and leading edge radiation therapy to the Seattle area community. At full capacity, the center will treat about 1,500 patients per year.

Olivier Legrain, Chief Executive Officer of IBA, said: *“Once again IBA has proved it can now deliver operational proton systems to cancer clinics and academic health centers in less than a year which is a clear achievement that underscores our competitive edge.”* He added, *“Importantly, this shortened set-up period helps to reduce the technological and financial risk for our stakeholders, hence making IBA the safest choice in the market today. With each new proton system installation, IBA continues to improve timelines, helping to ensure cancer centers open sooner and begin treating patients with protons more quickly.”*

Of the ten proton therapy centers currently operating in the United States, eight are IBA installations, including ProCure facilities in Oklahoma City, Oklahoma, Warrenville, Illinois and Somerset, New Jersey.

Hadley Ford, Chief Executive Officer of ProCure, added: *“There is a reason we continue to work with IBA. Working closely together we have improved the time to first patient treatment in every center we have opened. Patients can't afford to wait. Being able to opening months, or even years ahead of what other suppliers are capable of makes a huge difference. Others promise, IBA delivers”*

IBA is committed to making proton therapy, the most accurate cancer treatment, available worldwide. IBA is the only supplier to have multiple centers treating cancer patients with Pencil Beam Scanning (PBS), the most precise form of proton therapy. PBS enables Intensity Modulated Proton Therapy (IMPT), allowing clinicians to precisely target a cancerous tumor by controlling both the intensity and the spatial distribution of the dose to the millimeter.

About Proton Therapy

Proton therapy is increasingly considered the most advanced and targeted cancer treatment due to its superior dose distribution and fewer side effects. Protons deposit the majority of their effective energy within a precisely controlled range, directly within the tumor and sparing healthy surrounding tissue.



Press release |

As access to proton therapy increases in Europe and across the world, IBA continues to demonstrate compassionate innovations with more patient-friendly treatment rooms and more precise therapies. IBA proton therapy systems account for more than half of the world's clinically based proton therapy facilities. To date they include 13 operational proton therapy centers worldwide, and 12 more centers in development.

About IBA

IBA (Ion Beam Applications S.A.), is a cancer diagnostics and treatment company and the worldwide technology leader in the field of proton therapy. The company's expertise lies in the development of next generation proton therapy technologies and radiopharmaceuticals that provide oncology care providers with premium quality services and equipment, including IBA's leading fully integrated IntegraLab[®] radiopharmacy system, and Dosimetry advanced solutions for Quality Assurance of medical equipment and increased patient safety.

Headquartered in Belgium and employing more than 1,200 people worldwide, IBA currently has installed systems across Europe and the US and is expanding into emerging markets.

The Company is focused on building sustainable global growth for investors, providing solutions in the fight against cancer.

IBA is listed on the pan-European stock exchange EURONEXT. (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB) and more information can be found at: www.iba-worldwide.com

About ProCure Treatment Centers, Inc.

ProCure Treatment Centers, Inc. is a privately held healthcare company dedicated to improving the lives of patients with cancer by increasing access to proton therapy. The company was founded in 2005 in Bloomington, Ind., and is the first to develop a network of proton therapy centers in cities across the United States. The ProCure Proton Therapy Center in Oklahoma City opened in July 2009, the CDH Proton Center, A ProCure Center, located in Warrenville, Ill., opened in October 2010 and the ProCure Proton Therapy Center in Somerset, N.J., opened in March 2012. ProCure's fourth center is under construction in Seattle, Wash. (starting treatment in Q1 2013). ProCure provides management leadership and a comprehensive approach for the design, construction, financing, staffing, training and day-to-day operations of proton therapy centers. ProCure's solution reduces the time, cost and effort necessary to build and operate a facility. ProCure is advancing proton therapy through innovation and improvements in technology, and by providing training at the world's only educational facility specializing in proton therapy. For more information, visit www.procure.com

About Seattle Cancer Care Alliance

Seattle Cancer Care Alliance (SCCA) is a cancer treatment center that unites doctors from Fred Hutchinson Cancer Research Center, UW Medicine and Seattle Children's. Our goal, every day, is to turn cancer patients into cancer survivors. Our purpose is to lead the world in the prevention and treatment of cancer. SCCA has three clinical care sites: an outpatient clinic on the Hutchinson Center campus; a paediatric inpatient unit at Seattle Children's; an adult inpatient unit at UW Medical Center; and a radiation oncology clinic on the campus of Northwest Hospital. For more information about SCCA, visit www.seattlecca.org



Press release |

Contact

Olivier de Sadeleer

IBA

Marketing Manager

Phone : +32 10 203 342

E-mail. Olivier.deSadeleer@iba-group.com

Thomas Ralet

IBA

Vice-President Corporate Communication

+32 10 475 890

communication@iba-group.com

For media and investor enquiries:

M:Communications

Mary-Jane Elliott, Amber Bielecka, Claire Dickinson

+44 (0) 207 920 2333

IBA@mcomgroup.com